$PDSB

PDS Biotech (PDSB) announced that NantWorks exercised warrants to buy 17.7 million shares at $0.22 each, raising $3.9 million. The warrants were part of a September 2026 private placement that generated $11.3 million. Analysts have a Buy rating with a $4.00 target, but TipRanks' AI rates it Neutral due to financial weaknesses and technical strengths.

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds Princeton, NJ, November 10, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused

B.Riley raised its price target for PDS Biotechnology (PDSB) to $4.00 from $3.00, maintaining a Buy rating. The stock has gained 97% year-to-date, trading at $1.52. The upgrade follows positive trial data for PDS0301 in liver-metastatic colorectal cancer. PDSB plans to submit a Phase 3 protocol by Q4 2024, with a trial start in Q1 2027. The company also announced leadership changes and a share structure amendment.

PDS Biotechnology updated its corporate presentation, reporting strong interim results for PDS0301 in combination with chemotherapy, including a 71.4% objective response rate and median OS exceeding 34 months in a Phase 2 mCRC trial. The company also highlighted upcoming data readouts and a planned Phase 3 protocol for PDS0301, as well as results for PDS0101 in a Phase 2 trial. PDS0101 is seeking partnerships for further development.

PDS Biotechnology has added Deborah Ramsdell, John Dawson, and Bruce Wendel to its board. Ramsdell has 35+ years in biotech, currently leading Pluvia Biotech. Dawson chairs Virocell Therapeutics and previously led Oxford Biomedica. Wendel has audit and governance experience in pharma.

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Ph

PDS Biotechnology (PDSB) stock fell 14.92% as shareholders registered 16.5M shares for resale. The company has negative equity (-$3.6M), tight liquidity, and quarterly cash burn of $2.8M. Analysts cite downside risks due to regulatory uncertainty, weak financials, and technical downtrend.

PDS Biotechnology (NASDAQ: PDSB) is planning a Phase III trial for PDS0301 in metastatic colorectal cancer. Early studies showed promising results, with a 70% response rate at six months. The company has discussed the trial design with the FDA and aims to start the trial in early 2027. PDS0301 is being evaluated in combination with hepatic artery infusion pump therapy, which showed durable responses and manageable side effects.

PDS Biotechnology (PDSB) shares rose 13.08% on October 13, 2026, driven by positive clinical data and a financing deal. The company reported a 36% objective response rate in a Phase 2 trial published in JAMA Oncology, outperforming historical benchmarks. PDSB also secured $11.3M in funding from Nant Capital, though at a dilutive price. The stock's recent surge reflects optimism around its immunotherapy pipeline and strategic partnerships, despite its fragile financials.

PDS Biotechnology (PDSB) will host a virtual KOL event on Oct 15, 2026, to discuss Phase 2 data for PDS0301 in treating metastatic colorectal cancer with liver metastases. The event features NCI investigator Jonathan M. Hernandez and includes a live Q&A.